Differences between the CD34+ and CD34- blast compartments in apoptosis resistance in acute myeloid leukemia

Haematologica

Volumn 88, Issue 5, 2003, Pages 497-508

  Van Stijn, Amber ^a   Van Der Pol, Marjolein A ^a   Kok, Alice ^a   Bontje, Petra M ^a   Roemen, Guido M J M ^a   Beelen, Rob H J ^a   Ossenkoppele, Gert J ^a   Schuurhuis, Gerrit J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

AML; Apoptosis; Bax; Bcl 2; Bcl XL; CD34a

Indexed keywords

CD34 ANTIGEN; GLYCOPROTEIN P; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; REGULATOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL COMPARTMENTALIZATION; CELL SELECTION; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HUMAN CELL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; WESTERN BLOTTING;

ACUTE DISEASE; ANTIGENS, CD; ANTIGENS, CD34; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; FLOW CYTOMETRY; HUMANS; LEUKEMIA, MYELOID; NEOPLASM PROTEINS; P-GLYCOPROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; TUMOR CELLS, CULTURED;

EID: 0038100502     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Campos L, Guyotat D, Archimbaud E, Devaux Y, Treille D, Larese A, et al. Surface marker expression in adult acute myeloid leukaemia: correlations with initial characteristics, morphology and response to therapy. Br J Haematol 1989;72:161-6.
2. Geller RB, Zahurak M, Hurwitz CA, Burke PJ, Karp JE, Piantadosi S, et al. Prognostic importance of immunophenotyping in adults with acute myelocytic leukaemia: the significance of the stem-cell glycoprotein CD34 (My10). Br J Haematol 1990;76:340-7.
3. Guinot M, Sanz GF, Sempere A, Arilla MJ, Jarque I, Gomis F, et al. Prognostic value of CD34 expression in de novo acute myeloblastic leukaemia. Br J Haematol 1991;79:533-4.
4. -phenotypes with shorter survival. Groupe d'Etude Immunologique des Leucemies (GEIL). Leukemia 1992;6:393-9.
5. Lee EJ, Yang J, Leavitt RD, Testa JR, Civin CI, Forrest A, et al. The significance of CD34 and TdT determinations in patients with untreated de novo acute myeloid leukemia. Leukemia 1992;6:1203-9.
6. Myint H, Lucie NP. The prognostic significance of the CD34 antigen in acute myeloid leukaemia. Leuk Lymphoma 1992; 7:425-9.
7. Porwit-MacDonald A, Janossy G, Ivory K, Swirsky D, Peters R, Wheatley K, et al. Leukemia-associated changes identified by quantitative flow cytometry. IV. CD34 overexpression in acute myelogenous leukemia M2 with t(8;21). Blood 1996; 87:1162-9.
8. Dalal BI, Wu V, Barnett MJ, Horsman DE, Spinelli JJ, Naiman SC, et al. Induction failure in de novo acute myelogenous leukemia is associated with expression of high levels of CD34 antigen by the leukemic blasts. Leuk Lymphoma 1997;26: 299-306.
9. Raspadori D, Lauria F, Ventura MA, Rondelli D, Visani G, de Vivo A, et al. Incidence and prognostic relevance of CD34 expression in acute myeloblastic leukemia: analysis of 141 cases. Leuk Res 1997;21:603-7.
10. Bradbury D, Zhu YM, Russell N. Regulation of Bcl-2 expression and apoptosis in acute myeloblastic leukaemia cells by granulocyte-macrophage colony-stimulating factor. Leukemia 1994;8:786-91.
11. Russell NH, Hunter AE, Bradbury D, Zhu YM, Keith F. Biological features of leukaemic cells associated with autonomous growth and reduced survival in acute myeloblastic leukaemia. Leuk Lymphoma 1995;16:223-9.
12. Keith FJ, Bradbury DA, Zhu YM, Russell NH. Inhibition of bcl2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C. Leukemia 1995;9:131-8.
13. Bradbury DA, Zhu YM, Russell NH. Bcl-2 expression in acute myeloblastic leukaemia: relationship with autonomous growth and CD34 antigen expression. Leuk Lymphoma 1997; 24:221-8.
14. Stoetzer OJ, Nussler V, Darsow M, Gullis E, Pelka-Fleischer R, Scheel U, et al. Association of bcl-2, bax, bcl-xL and interleukin-1 β-converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia. Leukemia 1996;10 Suppl 3:S18-S22.
15. Smith BD, Bambach BJ, Vala MS, Barber JP, Enger C, Brodsky RA, et al. Inhibited apoptosis and drug resistance in acute myeloid leukaemia. Br J Haematol 1998;102:1042-9.
16. Garrido SM, Cooper JJ, Appelbaum FR, Willman CL, Kopecky K, Banker DE. Blasts from elderly acute myeloid leukemia patients are characterized by low levels of culture- and drug-induced apoptosis. Leuk Res 2001;25:23-32.
17. Wuchter C, Karawajew L, Ruppert V, Buchner T, Schoch C, Haferlach T, et al. Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics. Leukemia 1999;13:1943-53.
18. Lowenberg B, van Putten WL, Touw IP, Delwel R, Santini V. Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia. N Engl J Med 1993;328:614-9.
19. Hunter AE, Rogers SY, Roberts IA, Barrett AJ, Russell N. Autonomous growth of blast cells is associated with reduced survival in acute myeloblastic leukemia. Blood 1993;82:899-903.
20. Pallis M, Zhu YM, Russell NH. Bcl-x(L) is heterogeneously expressed by acute myeloblastic leukaemia cells and is associated with autonomous growth in vitro and with P-glycoprotein expression. Leukemia 1997;11:945-9.
21. Banker DE, Groudine M, Willman CL, Norwood T, Appelbaum FR. Cell cycle perturbations in acute myeloid leukemia samples following in vitro exposures to therapeutic agents. Leuk Res 1998;22:221-39.
22. van den Heuvel-Eibrink MM, van der HB, te Boekhorst PA, Pieters R, Schoester M, Lowenberg B, et al. MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia. Br J Haematol 1997;99:76-83.
23. Borg AG, Burgess R, Green LM, Scheper RJ, Yin JA. Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival. Br J Haematol 1998;103:1083-91.
24. Kasimir-Bauer S, Ottinger H, Meusers P, Beelen DW, Brittinger G, Seeber S, et al. In acute myeloid leukemia, coexpression of at least two proteins, including P-glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat-shock protein 27, is predictive of the response to induction chemotherapy. Exp Hematol 1998;26:1111-7.
25. Legrand O, Simonin G, Perrot JY, Zittoun R, Marie JP. Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood 1998;91:4480-8.
26. van der Kolk DM, de Vries EG, Noordhoek L, van den BE, van der Pol MA, Muller M, et al. Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia. Leukemia 2001;15:1544-53.
27. Del Poeta G, Stasi R, Aronica G, Venditti A, Cox MC, Bruno A, et al. Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood 1996;87:1997-2004.
28. van der Pol MA, Broxterman HJ, Pater JM, van der Maas M, Weijers GWD, Scheffer GL, et al. Function of the ABC transporters, P-glycoprotein, multidrug resistance protein and breast cancer resistance protein, in minimal residual disease in acute myeloid leukemia. Haematologica 2003;88:134-47.
29. Kanda Y, Hamaki T, Yamamoto R, Chizuka A, Suguro M, Matsuyama T, et al. The clinical significance of CD34 expression in response to therapy of patients with acute myeloid leukemia: an overview of 2483 patients from 22 studies. Cancer 2000;88:2529-33.
30. Andreeff M, Jiang S, Zhang X, Konopleva M, Estrov Z, Snell VE, et al. Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia 1999;13:1881-92.
31. Campos L, Oriol P, Sabido O, Guyotat D. Simultaneous expression of P-glycoprotein and BCL-2 in acute myeloid leukemia blast cells. Leuk Lymphoma 1997;27:119-25.
32. Bradbury DA, Russell NH. Comparative quantitative expression of bcl-2 by normal and leukaemic myeloid cells. Br J Haematol 1995;91:374-9.
33. Banker DE, Groudine M, Norwood T, Appelbaum FR. Measurement of spontaneous and therapeutic agent-induced apoptosis with BCL-2 protein expression in acute myeloid leukemia. Blood 1997;89:243-55.
34. Kaufmann SH, Karp JE, Svingen PA, Krajewski S, Burke PJ, Gore SD, et al. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood 1998;91: 991-1000.
35. Campos L, Sabido O, Rouault JP, Guyotat D. Effects of BCL-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells. Blood 1994;84:595-600.
36. Campos L, Rouault JP, Sabido O, Oriol P, Roubi N, Vasselon C, et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993;81:3091-6.
37. Lauria F, Raspadori D, Rondelli D, Ventura MA, Fiacchini M, Visani G, et al. High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate. Leukemia 1997;11:2075-8.
38. Maung ZT, MacLean FR, Reid MM, Pearson AD, Proctor SJ, Hamilton PJ, et al. The relationship between bcl-2 expression and response to chemotherapy in acute leukaemia. Br J Haematol 1994;88:105-9.
39. Karakas T, Maurer U, Weidmann E, Miething CC, Hoelzer D, Bergmann L. High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann Oncol 1998;9:159-65.
40. Smyth MJ, Krasovskis E, Sutton VR, Johnstone RW. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci USA 1998;95:7024-9.
41. Pallis M, Russell N. P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway. Blood 2000;95:2897-904.
42. Johnstone RW, Cretney E, Smyth MJ. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 1999;93:1075-85.
43. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J Immunol Methods 1995; 184:39-51.
44. Martin SJ, Reutelingsperger CP, McGahon AJ, Rader JA, van Schie RC, LaFace DM, et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by over-expression of Bcl-2 and Abl. J Exp Med 1995;182:1545-56.
45. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994;84:1415-20.
46. Anthony RS, McKelvie ND, Cunningham AJ, Craig JI, Rogers SY, Parker AC. Flow cytometry using annexin V can detect early apoptosis in peripheral blood stem cell harvests from patients with leukaemia and lymphoma. Bone Marrow Transplant 1998;21:441-6.
47. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
48. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227:680-5.
49. van Stijn A, Kok A, van der Pol MA, Feller N, Roemen GM, Westra AH, et al. A flow cytometric method to detect apoptosis-related protein expression in minimal residual disease in acute myeloid leukemia. Leukemia 2003;17:780-6.
50. Lacombe F, Durrieu F, Briais A, Dumain P, Belloc F, Bascans E, et al. Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia. Leukemia 1997;11:1878-86.
51. van der Pol MA, Pater JM, Feller N, Westra AH, van Stijn A, Ossenkoppele GJ, et al. Functional characterization of minimal residual disease for P-glycoprotein and multidrug resistance protein activity in acute myeloid leukemia. Leukemia 2001;15:1554-63.
52. Broxterman HJ, Schuurhuis GJ, Lankelma J, Oberink JW, Eekman CA, Claessen AM, et al. Highly sensitive and specific detection of P-glycoprotein function for haematological and solid tumour cells using a novel nucleic acid stain. Br J Cancer 1997;76:1029-34.
53. Ciolli S, Leoni F, Caporate R, Pascarella A, Salti F, Rossi-Ferrini P. CD34 expression fails to predict the outcome in adult acute myeloid leukemia. Haematologica 1993;78:151-5.
54. Sperling C, Buchner T, Creutzig U, Ritter J, Harbott J, Fonatsch C, et al. Clinical, morphologic, cytogenetic and prognostic implications of CD34 expression in childhood and adult de novo AML. Leuk Lymphoma 1995;17:417-26.
55. Fruchart C, Lenormand B, Bastard C, Boulet D, Lesesve JF, Callat MP, et al. Correlation between CD34 expression and chromosomal abnormalities but not clinical outcome in acute myeloid leukemia. Am J Hematol 1996;53:175-80.
56. Arslan O, Akan H, Beksac M, Ozcan M, Koc H, Ilhan O, et al. Lack of prognostic value of CD34 in adult AML. Leuk Lymphoma 1996;23:185-6.
57. Kyoda K, Nakamura S, Hattori N, Takeshima M, Nakamura K, Kaya H, et al. Lack of prognostic significance of CD34 expression in adult AML when FAB M0 and M3 are excluded. Am J Hematol 1998;57:265-6.
58. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994;367:645-8.
59. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-7.
60. Norgaard JM, Langkjer ST, Palshof T, Clausen N, Pedersen B, Hokland P. Relation of blast cell survival and proliferation to chemotherapy resistance in AML. Br J Haematol 1996;93: 888-97.
61. Suarez L, Vidriales B, Garcia-Larana J, Lopez A, Mediavilla JD, Martin-Reina V, et al. Multiparametric analysis of apoptotic and multi-drug resistance phenotype in elderly patients with acute myeloid leukemia according to the blast cell maturation stage. Haematologica 2001;86:1287-95.
62. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998;92:2322-33.